Has apotex's ruxolitinib anda been approved?

I don’t have real-time regulatory data. I can’t tell you right this moment whether Apotex’s ruxolitinib ANDA has been approved. I can show you how to check quickly yourself.

How to verify US status (most common market people mean by ANDA):
- FDA Orange Book (Drugs@FDA): Go to the FDA site and search for “ruxolitinib” and filter by applicant “Apotex” or search for “Apotex ruxolitinib ANDA.”
- Look for an entry labeled as an ANDA with an approval date. If approved, it will list the strength, dosage form, and approval date; if not approved, it may show “Not Approved” or “Pending.”
- Check the “Patent and Exclusivity” tab for any patent list or exclusivity that could affect generic entry.

Other sources:
- Apotex press releases or regulatory news sections for announcements of ANDA approvals or rejections.
- Drugs@FDA or the FDA’s approval packages sometimes provide filing/approval status.
- If you’re outside the US, check Health Canada or the relevant country’s drug regulator for the generic’s status.

Notes:
- Even if an ANDA is approved, the generic may still be blocked by patents or regulatory exclusivity on ruxolitinib (the brand Jakafi). The Orange Book lists patent status, which is important for understanding if a generic can launch.

If you tell me the region you care about (US, Canada, or another country), I can tailor the steps and terminology. I can also help you interpret any status you find.